CCR5 and breast carcinoma: Maraviroc, that has already been licensed by FDA for the use in humans, prevents the development of hepatocellular carcinoma [97] in a mouse model and decreases pulmonary metastasis in a preclinical mouse model of breast cancer [62, 96], suggesting that CCR5 antagonists could be used as an adjuvant therapy to reduce the risk of metastasis in patients with the basal breast cancer subtype.